JSKN027 / Alphamab - LARVOL DELTA

Alphamab Oncology…is pleased to announce that the first patient has been successfully dosed in the phase I clinical study of JSKN027…for the treatment of advanced malignant solid tumors (study number: JSKN027-101) (HKEXnews) - "JSKN027-101 is an open-label, multi-center, Phase I clinical study, including dose-escalation and dose-expansion phases. This study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and preliminary anti-tumor activity of JSKN027 in patients with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D)."

Trial status • Solid Tumor

A Study of JSKN027 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Not yet recruiting | Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

First-in-human • New P1 trial • Colorectal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

IND application for JSKN027 was officially accepted by the CDE (HKEXnews) - "The Company plans to initiate a phase I clinical study of JSKN027 for the treatment of advanced malignant solid tumors, aiming to evaluate its safety, tolerability,pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in such patient population and to determine the maximum tolerated dose and/or recommended Phase II dose."

New P1 trial • Solid Tumor